Evidence map›Paper›PMID 36579599›Full record

ArticleJournal of personalized medicine2022

Analysis of Genetic Variants Associated with COVID-19 Outcome Highlights Different Distributions among Populations.

Carlo Fabrizio, Andrea Termine, Valerio Caputo, Domenica Megalizzi, Giulia Calvino, Giulia Trastulli, Arcangela Ingrascì, Simona Ferrante, Cristina Peconi, Angelo Rossini and 5 more

Abstract read
In one paragraph

Article in Journal of personalized medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Carlo FabrizioData Science Unit, IRCCS Santa Lucia Foundation c/o CERC, 00143 Rome, Italy.ORCID 0000-0002-7824-8423
Andrea TermineData Science Unit, IRCCS Santa Lucia Foundation c/o CERC, 00143 Rome, Italy.ORCID 0000-0003-4374-7430
Valerio CaputoGenomic Medicine Laboratory UILDM, IRCCS Santa Lucia Foundation, 00179 Rome, Italy.ORCID 0000-0002-3503-3318
Domenica MegalizziGenomic Medicine Laboratory UILDM, IRCCS Santa Lucia Foundation, 00179 Rome, Italy.ORCID 0000-0001-9517-0165
Giulia CalvinoGenomic Medicine Laboratory UILDM, IRCCS Santa Lucia Foundation, 00179 Rome, Italy.
Giulia TrastulliGenomic Medicine Laboratory UILDM, IRCCS Santa Lucia Foundation, 00179 Rome, Italy.ORCID 0000-0002-5056-5099
Arcangela IngrascìGenomic Medicine Laboratory UILDM, IRCCS Santa Lucia Foundation, 00179 Rome, Italy.
Simona FerranteGenomic Medicine Laboratory UILDM, IRCCS Santa Lucia Foundation, 00179 Rome, Italy.
Cristina PeconiGenomic Medicine Laboratory UILDM, IRCCS Santa Lucia Foundation, 00179 Rome, Italy.
Angelo RossiniMedical Services Direction, IRCCS Santa Lucia Foundation, 00179 Rome, Italy.ORCID 0000-0002-0173-7325
Antonino SalviaMedical Services Direction, IRCCS Santa Lucia Foundation, 00179 Rome, Italy.ORCID 0000-0001-7000-3424
Carlo CaltagironeDepartment of Clinical and Behavioral Neurology, IRCCS Santa Lucia Foundation, 00179 Rome, Italy.
Claudia StrafellaGenomic Medicine Laboratory UILDM, IRCCS Santa Lucia Foundation, 00179 Rome, Italy.ORCID 0000-0003-1334-0920
Emiliano GiardinaGenomic Medicine Laboratory UILDM, IRCCS Santa Lucia Foundation, 00179 Rome, Italy.
Raffaella CascellaDepartment of Biomedicine and Prevention, Tor Vergata University, 00133 Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The clinical spectrum of SARS-CoV-2 infection ranges from asymptomatic status to mild infections, to severe disease and death. In this context, the identification of specific susceptibility factors is crucial to detect people at the higher risk of severe disease and improve the outcome of COVID-19 treatment. Several studies identified genetic variants conferring higher risk of SARS-CoV-2 infection and COVID-19 severity. The present study explored their genetic distribution among different populations (AFR, EAS, EUR and SAS). As a result, the obtained data support the existence of a genetic basis for the observed variability among populations, in terms of SARS-CoV-2 infection and disease outcomes. The comparison of ORs distribution for genetic risk of infection as well as for disease outcome shows that each population presents its own characteristics. These data suggest that each country could benefit from a population-wide risk assessment, aimed to personalize the national vaccine programs and the preventative measures as well as the allocation of resources and the access to proper therapeutic interventions. Moreover, the host genetics should be further investigated in order to realize personalized medicine protocols tailored to improve the management of patients suffering from COVID-19.

Indexed as

Coronavirus Disease 19 outcomesCOVID-19genetic distributionpersonalized programspopulationsSARS-CoV-2

Identifiers

PMID36579599
PMCPMC9692526

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.